This phase II trial utilized a rabbit antibody immunohistochemistry (IHC) assay to stratify study participants based on the percent expression of DLL3 found in tumor samples with at least 25% expression defined as DLL3-positive and at least 75% expression defined as DLL3-high. This evidence concerns the gene DLL3 and neoplasm.